06:56:07 Europe / Stockholm

Svenska | English

Alvotech

Kalender

2024-11-13	Kvartalsrapport 2024-Q3
2024-08-16	Kvartalsrapport 2024-Q2
2024-05-17	Kvartalsrapport 2024-Q1
2023-11-14	Kvartalsrapport 2023-Q3
2023-08-17	Kvartalsrapport 2023-Q2
2023-06-06	Årsstämma 2023
2023-05-19	Kvartalsrapport 2023-Q1

Beskrivning

Land	Island
Lista	Large Cap Iceland
Sektor	Hälsovård
Industri	Medicinteknik

Filter

År

Typ

Språk

Rensa

2024-04-03 13:41:08 Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 +0,31%

2024-04-03 12:43:56 Alvotech streymir kynningu fyrir fjárfesta 3. apríl 2024 kl. 12:15 að íslenskum tíma +0,31%

2024-04-03 12:43:56 Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 +0,31%

2024-03-22 21:15:00 Alvotech Announces Increase in Number of Own Shares -0,48%

2024-03-22 21:15:00 Alvotech tilkynnir um útgáfu eigin hlutabréfa -0,48%

2024-03-22 21:15:00 Alvotech Announces Increase in Number of Own Shares -0,48%

2024-03-20 21:15:00 Alvotech birtir uppgjör fyrir árið 2023 og kynnir nýjustu áfanga í rekstri félagsins -0,48%

2024-03-20 21:15:00 Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update -0,48%

2024-03-05 22:01:00 Alvotech heldur uppgjörsfund fyrir árið 2023 í beinu streymi þann 21. mars nk. kl. 12:00 að íslenskum tíma +2,27%

2024-03-05 22:01:00 Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET +2,27%

2024-03-05 22:00:00 Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET +2,27%

2024-02-29 22:05:00 Alvotech Appoints Interim Chief Quality Officer -0,91%

2024-02-29 22:05:00 Alvotech skipar nýjan framkvæmdastjóra gæðamála -0,91%

2024-02-29 22:05:00 Alvotech Appoints Interim Chief Quality Officer -0,91%

2024-02-26 10:25:00 Alvotech gengur að tilboði um sölu hlutabréfa að fjárhæð um 22,8 milljarðar króna (um 166 milljónir dala) á genginu 2.250 krónur (16,41 dalir) á hlut +11,36%

2024-02-26 10:25:00 Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share +11,36%

2024-02-24 02:15:09 Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® +11,36% | 27120 MISK

2024-02-24 02:15:00 Alvotech hlýtur markaðsleyfi í Bandaríkjunum fyrir Simlandi, líftæknilyfjahliðstæðu við Humira í háum styrk +11,36% | 27120 MISK

2024-02-24 02:15:00 Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® +11,36% | 27120 MISK

2024-02-15 12:30:00 Alvotech tilkynnir hvenær sala á AVT04, líftæknilyfjahliðstæðu við Stelara, getur hafist á alþjóðlegum mörkuðum +1,83%

2024-02-15 12:30:00 Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab) +1,83%

2024-01-29 10:00:00 Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® +5,58%

2024-01-29 10:00:00 Alvotech kynnir jákvæða niðurstöður úr rannsókn á lyfjahvörfum AVT03, fyrirhugaðrar líftæknilyfjahliðstæðu við Prolia og Xgeva +5,58%

2024-01-29 10:00:00 Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® +5,58%

2024-01-19 17:30:00 Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 +0,88%

2024-01-19 17:30:00 Alvotech birtir upplýsingar um stöðu umsókna um markaðsleyfi fyrir AVT02 og AVT04 í Bandaríkjunum +0,88%

2024-01-19 17:30:00 Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 +0,88%

2024-01-10 09:30:00 STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara -1,75%

2024-01-10 09:30:00 Alvotech og STADA hljóta markaðsleyfi fyrir fyrstu líftæknilyfjahliðstæðuna við Stelara í Evrópu -1,75%

2024-01-10 09:30:00 STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara -1,75%

2024-01-03 09:30:00 Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept) +2,88%

2024-01-03 09:30:00 Niðurstaða rannsóknar á sjúklingum sýnir sömu klínísku virkni AVT06 líftæknilyfjahliðstæðu Alvotech og Eylea +2,88%

2024-01-03 09:30:00 Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept) +2,88%

2023-11-29 10:00:00 Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® -3,12%

2023-11-29 10:00:00 Alvotech kynnir jákvæðar niðurstöður úr rannsókn á lyfjahvörfum AVT05, fyrirhugaðri líftæknilyfjahliðstæðu við Simponi® og Simponi Aria® -3,12%

2023-11-29 10:00:00 Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® -3,12%

2023-11-28 22:15:00 Alvotech birtir uppgjör fyrir fyrstu níu mánuði ársins 2023 og kynnir helstu áfanga á liðnum ársfjórðungi -1,81%

2023-11-28 22:15:00 Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update -1,81%

2023-11-28 22:15:00 Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update -1,81%

2023-11-21 14:00:00 Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET +1,19%

2023-11-21 14:00:00 Alvotech mun birta uppgjör fyrstu níu mánaða 2023 þann 28. nóvember og streyma uppgjörsfundi 29. nóvember kl. 13:00 að íslenskum tíma +1,19%

2023-11-21 14:00:00 Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET +1,19%

2023-11-14 13:00:00 Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab) +1,54%

2023-11-14 13:00:00 Alvotech og JAMP Pharma hljóta markaðsleyfi í Kanada fyrir Jamteki, líftæknilyfjahliðstæðu við Stelara +1,54%

2023-11-14 13:00:00 Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab) +1,54%

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Alvotech

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden